2C-B

Not to be confused with tusi, a recreational drug in pink-dyed powder form that contains a mixture of different drugs.

2C-B

Clinical data
Other names	4-bromo-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-bromophenethylamine; Nexus; Venus; Bromo; Bees; Erox; Synergy; Performax; Toonies [1]
Routes of administration	By mouth, insufflation, rectal
Drug class	Serotonergic psychedelic; Hallucinogen; Serotonin 5-HT2 receptor agonist
Legal status
Legal status	AU: S9 (Prohibited substance) BR: Class F2 (Prohibited psychotropics) CA: Schedule III DE: Anlage I (Authorized scientific use only) UK: Class A US: Schedule I UN: Psychotropic Schedule II
Pharmacokinetic data
Metabolism	Liver (MAO and CYP450) [1]
Metabolites	BDMPE, BDMPAA, BDMBA, and others [2]
Onset of action	Oral: 20–90 min [2]
Elimination half-life	2.48 ± 3.20 h [3]
Duration of action	Oral: 2–8 hours [2] [1]
Excretion	Urine [2] [1]
Identifiers
IUPAC name 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine
CAS Number	66142-81-2
PubChem CID	98527
DrugBank	DB01537
ChemSpider	88978
UNII	V77772N32H
KEGG	C22775
ChEBI	CHEBI:189669
ChEMBL	ChEMBL292821
CompTox Dashboard (EPA)	DTXSID10216332
ECHA InfoCard	100.164.088
Chemical and physical data
Formula	C10H14BrNO2
Molar mass	260.131 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1cc(CCN)c(OC)cc1Br
InChI InChI=1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3 Key:YMHOBZXQZVXHBM-UHFFFAOYSA-N

2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug. ^{[2] [1] [4]} It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy. To date, there is limited scientific information regarding the drug's pharmacokinetics and pharmacological effects in humans. The existing studies primarily classify 2C-B as a stimulant and hallucinogen, and less commonly an entactogen and empathogen. ^[5]

2C-B, also referred to by a number of slang names, is known to circulate in the illicit market in multiple forms: ^{[6] [7]} as a powder, in capsules or pills. For recreational use, the substance is generally consumed orally or nasally. In Shulgin's book PiHKAL , the oral dosage range is listed as 12–24 mg. ^[8]

History

2C-B was synthesized from 2,5-dimethoxybenzaldehyde by American chemist Alexander Shulgin in 1974. It first saw use among the psychiatric community as an aid during therapy, but was abandoned due to gastrointestinal effects and the lack of empathogenic effects. ^[1] 2C-B was first sold commercially as a purported aphrodisiac ^[9] under the trade name "Erox", which was manufactured by the German pharmaceutical company Drittewelle. ^[10] For several years, it was available as tablets in Dutch smart shops under the name "Nexus" and "B-Dub".^{[ citation needed ]}

Patterns of use

Recreational

1000mg of 2C-B

2C-B first became popularized in the United States as a short-lived substitute for the street drug ecstasy (MDMA) when the latter became illegal in 1985. ^[11] Many 2C-B users are young adults who attend raves. ^[6] Though 2C-B is still used in the rave subculture, commonly mistaken for and/or sold as ecstasy, its intentional use has become more common in the 2000s. ^[12]

In 2011, street prices in the United States ranged between $10 and $30 per tablet when purchased in small quantities. ^[6] Larger retail purchases cost between $200 and $500 per gram. Wholesale purchases of 2C-B would lower the price ($100 to $300 per gram in 2001, $30 to $100 on the darknet in 2020). ^[9]

Entheogenic use

There are claims that 2C-B was used as entheogen by the Sangoma, Nyanga, and Amagqirha people in place of their traditional plants; they refer to the chemical as Ubulawu Nomathotholo, which roughly translates to "Medicine of the Singing Ancestors". ^{[13] [14] [15]}

Effects

2C-B pill with heart logo

Little academic research has been conducted on the effects of 2C-B in humans. The information available is largely anecdotal and limited. Effects are often described as being more easily managed than other psychedelics; ^{[16] [17]} it is often compared to a mixture of a serotonergic psychedelic and MDMA. ^[18] At 5–10 mg, experiments with young chickens have shown it to produce effects similar to a low dosage of amphetamines. ^[19]

The anecdotal effects of 2C-B that have been reported by users on online discussion forums include: ^{[20] [21] [22]}

• At low doses, the experience may shift in intensity from engaging to mild/undetectable. Experienced users report the ability to take control of the effects and switch from engaged to sober at will.
• The hallucinations have a tendency to decrease and then increase in intensity, giving the users a sense of "waves" or even glowing. These are popularly described as "clichéd '70s visuals" or objects taking on "water color"-like textures.
• While the effects of the drug often render users unable to concentrate deeply on anything in particular, some can become engrossed in an activity such as watching a movie or playing a video game, distracting themselves from the visual and auditory effects of the drug.
• Excessive giggling or smiling is common, as is a tendency for deeper "belly laughs".
• Some users say that the effects are more intense when listening to music and report that they can see sounds and noises.
• Some users experience a decrease in visual acuity, although others report sharper vision.
• Through increased awareness of one's body, attention may be brought to perceived "imperfections" or internal body processes.
  
  The following effects are highly dose-dependent.
• Open eye visuals (OEVs), such as cartoon-like distortions and red or green halos around objects. Closed eye visuals (CEVs) are more common than OEVs.
• Affects and alters ability to communicate, engage in deep thought, or maintain attention span.
• Some users report experiencing frightening or fearful effects during the experience. Users describe feeling frigid or cold on reaching a plateau, while others feel wrapped in comfortable blankets/ultimate pleasure.
• Coordination may be affected; some users lose balance or have perceptual distinction problems.
• Onset time of 2C-B is highly dose dependent, but usually from 45 to 75 minutes. Taken on a full stomach, the onset time is increased to two hours or more.
• Before it was scheduled, 2C-B was sold in small doses as an aphrodisiac (see History). Some users report aphrodisiac effects at lower doses. ^{[23] [21]}
  
  

Clinical studies in humans suggest that 2C-B is a psychedelic with some possible entactogen-like effects. ^{[5] [3] [24]} Specific effects have included slight hallucinogenic states, perceptual changes, ego dissolution, time dilation, euphoria, feelings of well-being, reduced anger, increased reactivity to negative emotional stimuli, decreased ability to recognize expressions of happiness, augmented emotionality in speech, and mild sympathomimetic effects such as pressor effects, among others. ^{[5] [3] [24]}

Side effects

• Some users report mild "jitters" (body tremors), shuddering breath, and/or mild muscle spasms after insufflating 2C-B. Whether or not these effects are enjoyable depends on the user;
• Mild to intense diarrhea, gas, nausea, and general gastrointestinal discomfort;
• Severe headaches after coming down from large doses have been reported. However, many users report a lack of "comedown" or "crash", instead noting a gradual return to sobriety;
• At doses over 30–40 mg the user may experience frightening hallucinations, as well as tachycardia, hypertension, and hyperthermia; ^[25]
• 2C-B HCl is very painful to insufflate. Anecdotal evidence suggests that 2C-B HBr, the hydrobromide salt with greater water solubility, is less irritating to the mucous membranes lining the nose but slightly less potent when compared dose-for-dose with the HCl salt; ^[26]
• Rectal administration of a water-based solution of 2C-B is known to be less painful than insufflation and much more potent than oral administration.

Duration

When orally consumed, 2C-B has a much longer delay before the onset of effects than when it is insufflated. Oral ingestion generally takes roughly 45–75 minutes for the effects to be felt, plateau lasts 2–4 hours, and coming down lasts 1–2 hours. Rectal administration onset varies from 5–20 minutes. Insufflated onset takes 1–10 minutes for effects to be felt. The duration can last from 4 to 12 hours depending on route of administration, dose, and other factors. ^[20]

With insufflation, the effects are more abrupt and intense but have a significantly shorter duration, while oral usage results in a milder, longer experience. When insufflated, the onset happens very rapidly, usually reaching the peak at about 20–40 minutes and plateauing for 2–3 hours. 2C-B is also considered one of the most painful drugs to insufflate, with users reporting intense nasal burning. ^[16] The sudden intensity of the experience combined with the pain can often start the experience with a negative imprint and nausea is also increased with insufflation, compounding the issue.

Toxicity and dosage

The September 1998 issue of Journal of Analytical Toxicology reported that very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-B. The relationship between its use and death is unknown. ^[9] The common oral recreational dose is around 15–25 mg, ^[27] at which visual and auditory effects are experienced. Severe adverse reactions are extremely rare, but use of 2C-B was linked to significant brain injury in one case report; the alleged "2C-B" was never actually discovered by testing so the only evidence suggesting 2C-B was the cause was the victim's own words, without taking into consideration that adulteration and impurities are very common in illicit drugs. ^[28]

	Oral	Insufflated
ED50	10 mg	4–6 mg
Moderate	15–25 mg	5–9 mg
Strong	26–35 mg	10–20 mg
Extremely Intense	>35 mg	>20 mg
Duration	4–8 hours	2–4 hours

The lethal dosage is unknown. It was reported in PiHKAL , by Alexander Shulgin, that a psychologist had accidentally taken a 100 mg dose orally without apparent harm. ^[8]

When sold as "Ecstasy", tablets containing 2C-B often contain about 5 mg of the drug, an amount which produces stimulatory effects that mimic the effects of MDMA; in contrast, tablets marketed as 2C-B have larger quantities of the drug (10–20 mg) which cause hallucinogenic effects. ^[29] Street purity of 2C-B, when tested, has been found to be relatively high. ^[30] Researchers in Spain found that 2C-B samples in the country doubled between 2006 and 2009, switched from primarily powder form to tablets, and exhibited "low falsification rates". ^[18] An analysis of street samples in the Netherlands found impurities "in small percentages"; only one of the impurities, the N-acetyl derivative of 2C-B, could be identified, and comprised 1.3% of the sample. The authors suggested that this compound was a by-product of 2C-B synthesis. ^[29]

Pharmacology

Pharmacodynamics

2C-B activities

Target	Affinity (Ki, nM)
5-HT1A	240–311
5-HT1B	104
5-HT1D	26
5-HT1E	120
5-HT1F	ND
5-HT2A	0.66–32 (Ki) 1.6–80 (EC50 Tooltip half-maximal effective concentration) 45–99% (Emax Tooltip maximal efficacy)
5-HT2B	13.5–97 75–130 (EC50) 52–89% (Emax)
5-HT2C	32–90 0.03–4.1 (EC50) 104–116% (Emax)
5-HT3	>10,000
5-HT4	ND
5-HT5A	>10,000
5-HT6	320
5-HT7	210
α1A	>10,000
α1B	>10,000
α1D	ND
α2A	309–320
α2B	>10,000
α2C	103
β1	>10,000
β2	>10,000
β3	ND
D1	12,000
D2	2,200–25,200
D3	7,116–10,000
D4	>10,000
D5	>10,000
H1–H4	>10,000
M1–M2	>10,000
M3	822
M4–M5	>10,000
I1	2,155
σ1	>10,000
σ2	>10,000
TAAR1 Tooltip Trace amine-associated receptor 1	90–3,000 (Ki) (rodent) 3,300–7,190 (EC50) (human)
SERT Tooltip Serotonin transporter	9,700–13,300 (Ki) 18,000–312,900 (IC50 Tooltip half-maximal inhibitory concentration)
NET Tooltip Norepinephrine transporter	27,400–31,000 (Ki) 44,000–67,100 (IC50)
DAT Tooltip Dopamine transporter	6,500–>30,000 (Ki) 231,000 (IC50)
MAO-A Tooltip Monoamine oxidase A	125,000 (IC50)
MAO-B Tooltip Monoamine oxidase B	58,000 (IC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [31] [32] [33] [34] [1] [35] [36] [37] [38] [39]

Unlike most psychedelics, 2C-B has been shown to be a low efficacy human serotonin 5-HT_2A and 5-HT_2C receptor partial agonist. ^[40] This suggests that activation of the 5-HT_2A-coupled phospholipase D pathway ^[40] or functional antagonism of 5-HT_2A may also play a role. The rank order of 5-HT_2A receptor antagonist potency for this family of drugs in Xenopus is 2C-I > 2C-B > 2C-D > 2C-H. ^[41]

Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine (EC₅₀ Tooltip half-maximal effective concentration = >100,000 nM or "inactive"). ^{[42] [43]} Likewise, these other 2C derivatives showed little activity as serotonin 5-HT_1A receptor agonists (EC₅₀ = >3,000 nM). ^[43]

Pharmacokinetics

Metabolism

2C-B has been shown to be metabolized by liver hepatocytes, resulting in deamination and demethylation that produces several products. Oxidative deamination results in the 2-(4-bromo-2,5-dimethoxyphenyl)-ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) metabolites. Additionally, 4-bromo-2,5-dimethoxybenzoic acid (BDMBA) can also be produced by oxidative deamination. Further metabolism of BDMPE and BDMPAA may occur by demethylation. Alternatively, the later metabolites can be generated by demethylation of 2C-B followed by oxidative deamination. ^[25]

There is species differentiation in the metabolism of 2C-B. Mice hepatocytes produce 4-bromo-2,5-dimethoxy-phenol (BDMP), a previously unknown metabolite. Meanwhile, human, monkey and rabbit hepatocytes produce 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), but dog, rat and mouse hepatocytes do not. ^[25] 2C-B also reduces aggressive responses in drugged rats. ^[44]

Chemistry

Analogues and derivatives

Analogues and derivatives of 2C-B:

25-N:

• 25B-N1POMe
• 25B-NAcPip

25-NB:

• 25B-NB
• 25B-NB23DM
• 25B-NB25DM
• 25B-NB3OMe
• 25B-NB4OMe
• 25B-NBF
• 25B-NBMD
• 25B-NBOH
• 25B-NBOMe (NBOMe-2CB)
  • DMBMPP

25-NM:

• 25B-NMe7BF
• 25B-NMe7BT
• 25B-NMe7Bim
• 25B-NMe7Box
• 25B-NMe7DHBF
• 25B-NMe7Ind
• 25B-NMe7Indz
• 25B-NMePyr

Substituted benzofurans:

• 2C-B-FLY
  • 2C-B-BUTTERFLY
  • 2C-B-DRAGONFLY
• 2CBFly-NBOMe (NBOMe-2CB-Fly)
• DOB-FLY
• DOB-2-DRAGONFLY-5-BUTTERFLY

N-(2C)-fentanyl:

• N-(2C-B) fentanyl ^[45]
  • N-(2C-B-FLY) fentanyl ^[46]

Other:

• BOB
• BOH-2C-B, β-Hydroxy-2C-B, βOH-2CB ^{[47] [48]}
• BMB
• 2C-B-5-hemifly
• 2C-B-aminorex (2C-B-AR)
• 2C-B-AN
• 2C-B-BZP
• 2C-B-FLY-NB2EtO5Cl
• 2C-B-PP
• 2CB-Ind
• βk-2C-B (beta-keto 2C-B)
• N-Ethyl-2C-B
• TCB-2 (2C-BCB)

A variety of N-substituted derivatives of 2C-B have been tested, including N-methyl-2CB, N,N-dimethyl-2CB, N-ethyl-2CB and N-benzyl-2CB. Most simple alkyl derivatives were considerably less potent than 2C-B, with N-ethyl-2CB for instance having a 40 times lower affinity for the 5-HT_2A receptor. The N-benzyl derivative however was found to have higher binding affinity than 2C-B itself, with N-(4-bromobenzyl)-2CB binding even more tightly. ^[49] This initial research did not include functional assays of activity, but later led to the development of potent substituted N-benzyl derivatives such as 25B-NBOMe, ^[50] and 25B-NBOH. βk-2C-B shows dramatically reduced potency and efficacy as a serotonin 5-HT_2A receptor agonist compared to 2C-B. ^[37]

Reagent results

Exposing compounds to the reagents gives a colour change which is indicative of the compound under test.

Marquis	Mecke	Mandelin	Liebermann	Froehde	Robadope
Yellow to green	Yellow to olive brownish	green	Yellow to black	Yellow to green	Slow pink
Ehrlich	Hofmann	Simon's	Scott	Folin
No reaction	No reaction	No reaction	No reaction	(Light) purple

Legal status

United Nations

The UN Commission on Narcotic Drugs added 2C-B to Schedule II of the Convention on Psychotropic Substances in March 2001. ^[51]

2C-B is a scheduled drug in most jurisdictions. ^[52] The following is a partial list of territories where the substance has been scheduled.

Countries

Argentina

2C-B is controlled under the List 1, as well as similar substances like 2C-I or 2C-T-2. ^[53]

Australia

2C-B is controlled in Australia and on the list of substances subject to import and export controls (Appendix B). It was placed on Schedule One of the Drugs Misuse and Trafficking Act when it first came to notice in 1994, when in a showcase legal battle chemist R. Simpson was charged with manufacturing the substance in Sydney. Alexander Shulgin came to Australia to testify on behalf of the defense, to no avail.

2C-B is not specifically listed in the Australia Poisons Standard (October 2015), however similar drugs such as 2C-T-2 and 2C-I are making 2C-B fall under the Australian analogue act. ^[54]

Belgium

In Belgium, 2C-B is a controlled substance making production, distribution, and possession illegal.

Brazil

In Brazil, 2C-B is a controlled substance making production, distribution, and possession illegal.

Canada

In Canada, 2C-B is classified under Controlled Drugs and Substances Act as Schedule III as "4-bromo-2,5-dimethoxybenzeneethanamine and any salt, isomer or salt of isomer thereof". ^[55]

2C-B has been rescheduled (Schedule III), in a new amendment, taking effect on October 31, 2016. This is to include the other 2C-x analogues. ^[56]

Chile

In August 2007, 2C-B, along with many other psychologically active substances, ^[57] was added to Ley 20.000, known as the Ley de Drogas  [ es ].

Czech Republic

Possession of more than 200 mg of 2C-B is punishable with a two years jail sentence. ^[58] Smaller amount is punishable by a fine. The 200 mg threshold is merely a guideline which the court can reconsider depending on circumstances.

Denmark

In Denmark, 2C-B is listed as a category B drug. ^[59]

Estonia

In Estonia, 2C-B is classified as Schedule I.

Germany

In Germany, 2C-B is controlled in the Betäubungsmittelgesetz (BtMG) Anlage I as "Bromdimethoxyphenethylamin" (BDMPEA).

Italy

2C-B is schedule I (tabella I). ^[60]

Japan

In Japan, 2C-B was scheduled in 1998. It was previously marketed as "Performax".

Luxembourg

In Luxembourg, 2C-B is a prohibited substance since 2001. ^[61]

Netherlands

In the Netherlands, 2C-B was scheduled on July 9, 1997.

In the Netherlands, 2C-B became a list I substance of the Opium Law despite no health incidents occurring. Following the ban, other phenethylamines were sold in place of 2C-B until the Netherlands became the first country in the world to ban 2C-I, 2C-T-2 and 2C-T-7 alongside 2C-B.

Norway

In Norway, 2C-B was classified as Schedule II on March 22, 2004, listed as 4-bromo-2,5-dimethoxyphenethylamine. ^[62]

Poland

2C-B is schedule I (I-P group) in Poland.

Russia

Banned as a narcotic drug with a criminal penalty for possession of at least 10 mg. ^[63]

Spain

In Spain, 2C-B was added to Category 2 prohibited substances in 2002.

Sweden

2C-B is currently classified as Schedule I in Sweden.

2C-B was first classified as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor  [ sv ] (Act on the Prohibition of Certain Goods Dangerous to Health) as of April 1, 1999, under SFS 1999:58 ^[64] that made it illegal to sell or possess. Then it became schedule I as of June 1, 2002, published in LVFS 2002:4 ^[65] but mislabeled "2-CB" in the document. However, this was corrected in a new document, LVFS 2009:22 ^[66] effective December 9, 2009.

Switzerland

In Switzerland, 2C-B is listed in Anhang D of the DetMV and is illegal to possess. ^[67]

UK

All drugs in the 2C family are Class A under the Misuse of Drugs Act which means they are illegal to produce, supply or possess. Possession carries a maximum sentence of seven years imprisonment while supply is punishable by life imprisonment and an unlimited fine. ^[68]

United States

In the United States, 2C-B is classified as a Schedule I controlled substance. This became permanent law on June 2, 1995 ^[69] following a proposal by the Drug Enforcement Administration in December 1994. ^[70]

References

1. Nugteren-van Lonkhuyzen JJ, van Riel AJ, Brunt TM, Hondebrink L (December 2015). "Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans". Drug Alcohol Depend. 157: 18–27. doi:10.1016/j.drugalcdep.2015.10.011. PMID   26530501.
2. Cole MD, Lea C, Oxley N (2002). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature". Sci Justice. 42 (4): 223–224. doi:10.1016/S1355-0306(02)71832-7. PMID   12632938.
3. Papaseit E, Farré M, Pérez-Mañá C, Torrens M, Ventura M, Pujadas M, et al. (2018). "Acute Pharmacological Effects of 2C-B in Humans: An Observational Study". Frontiers in Pharmacology. 9: 206. doi: 10.3389/fphar.2018.00206 . PMC   5859368 . PMID   29593537.
4. Caudevilla-Gálligo F, Riba J, Ventura M, González D, Farré M, Barbanoj MJ, et al. (July 2012). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects". Journal of Psychopharmacology. 26 (7): 1026–1035. doi:10.1177/0269881111431752. PMID   22234927. S2CID   35535891.
5. González D, Torrens M, Farré M (2015-10-12). "Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions". BioMed Research International. 2015: 643878. doi: 10.1155/2015/643878 . PMC   4620274 . PMID   26543863.
6. "2C-B Street Names" (PDF). February 1, 2011. Archived from the original (PDF) on October 16, 2012. Retrieved 2012-09-28.
7. Westhoff B (2019). Fentanyl, Inc. New York: Atlantic Monthly Press. p. 62. ISBN   978-1-0941-6390-1. OCLC   1136538402.
8. Shulgin AT (1991). Pihkal : a chemical love story. Ann Shulgin. Berkeley, CA: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
9. "2C-B (Nexus) Reappears on the Club Drug Scene" (PDF). National Drug Intelligence Center. Department of Justice. May 2001. Retrieved 11 February 2013.
10. "Drittewelle 2C-B Packaging". Erowid.org. 2002. Retrieved 25 September 2013.
11. Pachico E (1 November 2012). "2CB Now Drug of Choice for Colombia Elite". InSight Crime. Retrieved 11 February 2013.
12. Gahlinger P (2004). Illegal Drugs: A Complete Guide to Their History, Chemistry, Use and Abuse. Penguin. pp. 343–344. ISBN   9780452285057.
13. "2CB chosen over traditional entheogen's by South African healers". Tacethno.com. 2008-03-27. Retrieved May 15, 2012.
14. The Nexus Factor - An Introduction to 2C-B Erowid
15. Ubulawu Nomathotholo Pack Photo by Erowid. © 2002 Erowid.org
16. "Erowid 2C-B Vault: Basics". Erowid. 2011-02-20. Retrieved 2013-09-25.
17. Palamar JJ, Acosta P (January 2020). "A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines". Human Psychopharmacology. 35 (1): e2719. doi:10.1002/hup.2719. PMC   6995261 . PMID   31909513.
18. Caudevilla-Gálligo F, Riba J, Ventura M, González D, Farré M, Barbanoj MJ, et al. (July 2012). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects". Journal of Psychopharmacology. 26 (7): 1026–35. doi:10.1177/0269881111431752. PMID   22234927. S2CID   35535891.
19. Bronson ME, Jiang W, DeRuiter J, Clark CR (1995). "A behavioral comparison of Nexus, cathinone, BDB, and MDA". Pharmacology, Biochemistry, and Behavior. 51 (2–3): 473–475. doi:10.1016/0091-3057(95)00013-M. PMID   7667371. S2CID   32246652.
20. "Erowid 2C-B Vault: Effects". Erowid . Retrieved 2013-09-25.
21. "Drugscope: 2C-B". Drugscope. Jan 2004. Archived from the original on 2013-09-28. Retrieved 2013-09-25.
22. "2C-B - Dancesafe.org". Dancesafe . Retrieved 2013-09-25.
23. "Shulgin, A (1991) PIHKAL". Erowid.org. Retrieved May 15, 2012.
24. Mallaroni P, Mason NL, Reckweg JT, Paci R, Ritscher S, Toennes SW, et al. (August 2023). "Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition". Clin Pharmacol Ther. 114 (2): 423–433. doi:10.1002/cpt.2958. PMID   37253161.
25. Carmo H, Hengstler JG, de Boer D, Ringel M, Remião F, Carvalho F, et al. (January 2005). "Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human". Toxicology. 206 (1): 75–89. Bibcode:2005Toxgy.206...75C. doi:10.1016/j.tox.2004.07.004. PMID   15590110.
26. "Erowid 2C-B Vault : FAQ v1.0". erowid.org.
27. "Erowid 2C-B Vault : Dose/Dosage".
28. Ambrose JB, Bennett HD, Lee HS, Josephson SA (May 2010). "Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion". The Neurologist. 16 (3): 199–202. doi:10.1097/NRL.0b013e3181a3cb53. PMID   20445431. S2CID   35035721.
29. de Boer D, Gijzels MJ, Bosman IJ, Maes RA (1999). "More data about the new psychoactive drug 2C-B". Journal of Analytical Toxicology. 23 (3): 227–8. doi: 10.1093/jat/23.3.227 . PMID   10369336.
30. Cole MD, Lea C, Oxley N (October 2002). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature". Science & Justice. 42 (4): 223–4. doi:10.1016/S1355-0306(02)71832-7. PMID   12632938.^{[ permanent dead link ‍]}
31. "PDSP Database". UNC (in Zulu). Retrieved 3 December 2024.
32. Liu T. "BindingDB BDBM50005267 2,5-dimethoxy-4-bromophenethylamine::2-(4-Bromo-2,5-dimethoxy-phenyl)-ethylamine::2-(4-bromo-2,5-dimethoxyphenyl)ethylamine::CHEMBL292821::US20240166618, Compound 88". BindingDB. Retrieved 3 December 2024.
33. Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi: 10.1371/journal.pone.0009019 . PMC   2814854 . PMID   20126400.
34. Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)" (PDF). Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID   26318099.
35. Marcher-Rørsted E, Halberstadt AL, Klein AK, Chatha M, Jademyr S, Jensen AA, et al. (May 2020). "Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists". ACS Chem Neurosci. 11 (9): 1238–1244. doi:10.1021/acschemneuro.0c00129. PMID   32212672.
36. Luethi D, Trachsel D, Hoener MC, Liechti ME (May 2018). "Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)" (PDF). Neuropharmacology. 134 (Pt A): 141–148. doi:10.1016/j.neuropharm.2017.07.012. PMID   28720478.
37. Pottie E, Cannaert A, Stove CP (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Arch Toxicol. 94 (10): 3449–3460. Bibcode:2020ArTox..94.3449P. doi:10.1007/s00204-020-02836-w. PMID   32627074.
38. Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Test Anal. 11 (2): 318–324. doi:10.1002/dta.2494. PMID   30188017.
39. Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID   26791601.
40. Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, et al. (June 2007). "Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1054–61. CiteSeerX   10.1.1.690.3752 . doi:10.1124/jpet.106.117507. PMID   17337633. S2CID   11651502.
41. Villalobos CA, Bull P, Sáez P, Cassels BK, Huidobro-Toro JP (April 2004). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 4-HT2A receptor antagonists in Xenopus laevis oocytes". British Journal of Pharmacology. 141 (7): 1167–74. doi:10.1038/sj.bjp.0705722. PMC   1574890 . PMID   15006903.
42. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". Eur J Pharmacol. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. PMID   17223101.
43. Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology (Berl). 231 (5): 875–888. doi:10.1007/s00213-013-3303-6. PMC   3945162 . PMID   24142203.
44. Muehlenkamp F, Lucion A, Vogel WH (April 1995). "Effects of selective serotonergic agonists on aggressive behavior in rats". Pharmacology Biochemistry and Behavior. 50 (4): 671–4. doi:10.1016/0091-3057(95)00351-7. PMID   7617717. S2CID   12774131.
45. "Explore N-(2C-B)-Fentanyl | PiHKAL · info". isomerdesign.com.
46. "Explore N-(2C-FLY)-Fentanyl | PiHKAL · info". isomerdesign.com.
47. Glennon RA, Bondarev ML, Khorana N, Young R, May JA, Hellberg MR, et al. (November 2004). "β-Oxygenated Analogues of the 5-HT2ASerotonin Receptor Agonist 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane". Journal of Medicinal Chemistry. 47 (24): 6034–6041. doi:10.1021/jm040082s. ISSN   0022-2623. PMID   15537358.
48. Beta-hydroxyphenylalkylamines and their use for treating glaucoma
49. Glennon RA, Dukat M, el-Bermawy M, Law H, De los Angeles J, Teitler M, et al. (June 1994). "Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines". Journal of Medicinal Chemistry. 37 (13): 1929–35. doi:10.1021/jm00039a004. PMID   8027974.
50. Heim R (March 19, 2004). Synthese und Pharmakologie potenter 5-HT_2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts [Synthesis and pharmacology of potent 5-HT_2A receptor agonists which have a partial N-2-methoxybenzyl structure: Development of a new structure-activity concept] (Thesis) (in German). Free University of Berlin . Retrieved August 1, 2014.
51. "List of psychotropic substances under international control" (PDF). Green List (23rd ed.). International Narcotics Control Board. August 2003. Archived from the original (PDF) on 2 March 2007.
52. "Erowid 2C-B page".
53. "Last Argentina Controlled Drugs List" (PDF). Retrieved May 15, 2012.
54. Poisons Standard October 2015 https://www.comlaw.gov.au/Details/F2015L01534
55. "CDSA Schedule II". Archived from the original on 2020-07-25. Retrieved 2008-06-13.
56. "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Canada Gazette. Government of Canada, Public Works and Government Services Canada, Public Services and Procurement Canada, Integrated Services Branch, Canada. 2016-05-04.
57. "APRUEBA REGLAMENTO DE LA LEY Nº 20.000 QUE SANCIONA EL TRÁFICO ILÍCITO DE ESTUPEFACIENTES Y SUSTANCIAS SICOTRÓPICAS Y SUSTITUYE LA LEY Nº 19.366" (PDF).
58. "Erowid Psychoactive Vaults : Drug Laws : Czech Republic". erowid.org.
59. "Bekendtgørelse om euforiserende stoffer" (in Danish). 2008-07-01. Retrieved 2013-10-01.
60. "Italy Drug Schedule (Tabella I)". Archived from the original on 2011-06-27.
61. Règlement grand-ducal du 14 décembre 2001 modifiant l'annexe du règlement grand-ducal modifié du 4 mars 1974 concernant certaines substances toxiques.
62. "Norway Drug Schedule".
63. "Постановление Правительства РФ от 01.10.2012 N 1002 "Об утверждении значительного, крупного и особо крупного размеров наркотических средств и психотропных веществ, а также значительного, крупного и особо крупного размеров для растений, содержащих наркотические средства или психотропные вещества, либо их частей, содержащих наркотические средства или психотропные вещества, для целей статей 228, 228.1, 229 и 229.1 Уголовного кодекса Российской Федерации" (с изменениями и дополнениями)". base.garant.ru.
64. "Förordning (1999:58) om förbud mot vissa hälsofarliga varo" (in Swedish). 1999-02-25. Archived from the original on 2013-10-04. Retrieved 2013-10-01.
65. "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika: LVFS 2002:4" (PDF) (in Swedish). Archived from the original (PDF) on 2013-10-04. Retrieved 2013-09-14.
66. "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika: LVFS 2009:22" (PDF) (in Swedish). Archived from the original (PDF) on 2018-09-16. Retrieved 2013-09-14.
67. "Verzeichnis aller betäubungsmittelhaltigen Stoffe" [Directory of all narcotics-containing substances]. Swissmedic (in German). Swiss Agency for Therapeutic Products. 2011-08-18. p. 2. Archived from the original (PDF) on 2012-03-15. Retrieved 2013-11-30.
68. "2C family | FRANK". www.talktofrank.com. Archived from the original on 2024-10-07. Retrieved 2024-11-12.
69. "Federal Register, Volume 60 Issue 106 (Friday, June 2, 1995)". GovInfo . 1994-06-02. Archived from the original on 2023-11-04. Retrieved 2024-11-12.
70. "Federal Register, Volume 59 Issue 243 (Tuesday, December 20, 1994)". GovInfo. 1994-12-20. Archived from the original on 2024-05-20. Retrieved 2024-11-12.

External links

• 2C-B Entry in PiHKAL
• 2C-B Entry in PiHKAL • info
• Erowid 2C-B vault—includes reports from users of 2C-B, as well as scientific and government reports
• 2C-B Dosage chart